Cicletanine (HCl)

Overview

Categories

Primary Characterstics

It is of Synthetic origin and belongs to phenylthiazoles. It belongs to Protein kinase inhibitor pharmacological group on the basis of mechanism of action. The Molecular Weight of Dabrafenib is 615.68.

Indications

Back to top

Pharmacokinetics

Back to top

Contraindications

Back to top

Drug Interactions

Dabrafenib is known to interact with other drugs, the details of drug interactions is as follows:

Severity N/A

IVABRADINE

Interaction of IVABRADINE with Dabrafenib

Carbamazepine

Interaction of Carbamazepine with Dabrafenib

Details: Strong CYP3A4 inducers may decrease levels of dabrafenib.
Management: Consider alternate therapy.
Clarithromycin

Interaction of Clarithromycin with Dabrafenib

Details: Strong CYP3A4 inhibitors may increase levels of dabrafenib
Management: Consider alternate therapy.
Gemfibrozil

Interaction of Gemfibrozil with Dabrafenib

Details: Strong CYP3A4 inhibitors may increase levels of dabrafenib.
Management: consider alternate therapy
Ketoconazole

Interaction of Ketoconazole with Dabrafenib

Details: Strong CYP3A4 inhibitors may increase levels of dabrafenib
Management: Consider alternate therapy
Midazolam

Interaction of Midazolam with Dabrafenib

Details: Dabrafenib decreased systemic exposure of midazolam (a substrate of CYP3A4)
Management: Substitute for these medications or monitor patients for loss of efficacy.
Nefazodone (HCl)

Interaction of Nefazodone (HCl) with Dabrafenib

Details: Strong CYP3A4 inhibitors may increase levels of dabrafenib
Management: consider alternate therapy
Pantoprazole

Interaction of Pantoprazole with Dabrafenib

Details: Proton pump inhibitors may alter the solubility of dabrafenib and reduce its bioavailability
Phenobarbital Sodium

Interaction of Phenobarbital Sodium with Dabrafenib

Details: Strong CYP3A4 inducers may decrease levels of dabrafenib
Management: Consider alternate therapy
Phenytoin (Na)

Interaction of Phenytoin (Na) with Dabrafenib

Details: Strong CYP3A4 inducers may decrease levels of dabrafenib
Management: Consider alternate therapy
Ranitidine

Interaction of Ranitidine with Dabrafenib

Details: H2-receptor antagonists may alter the solubility of dabrafenib and reduce its bioavailability
Rifampicin

Interaction of Rifampicin with Dabrafenib

Details: Strong CYP3A4 inducers may decrease levels of dabrafenib
Management: consider alternate therapy

These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Back to top

Side Effects

Back to top

Dosage

Cicletanine (HCl)'s dosage details are as follows:
Dose Single Dose Frequency Route Instructions

Adult Dosage
50 to 100 mg75 (75)24 hourly

Paedriatic Dosage (20kg)
No data regarding the Paedriatic dosage details of Cicletanine (HCl) is available.

Neonatal Dosage (3kg)
No data regarding the neonatal dosage details of Cicletanine (HCl) is available.

High Risk Groups

Drug should not be given to Paediatrics, Pregnant Mothers, and Neonates.

If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Back to top

Warning / Precautions

Back to top

Storage Conditions

Back to top

Interference in Pathology

Back to top

Brands / Trade Names of Cicletanine (HCl)

Back to top

Manufacturers of Cicletanine (HCl) in Pakistan

Back to top

Previous Drug Generic - Next Drug Generic


Suggested Pages